Phenotypical Approach of the Drug Metabolizing Hormones Activity Before and After Roux-en Y-Gastric Bypass (SODA)
Primary Purpose
Obesity
Status
Completed
Phase
Phase 1
Locations
France
Study Type
Interventional
Intervention
phenotypical approach
Sponsored by

About this trial
This is an interventional treatment trial for Obesity focused on measuring drug metabolizing enzymes and drug transporter, Roux-en Y-Gastric Bypass, Obesity, Drug Availability, BMI over 35kg/m² and comorbidities or >40kg/m²
Eligibility Criteria
Inclusion Criteria:
- Patients with morbid obesity (IMC > 40 kg/m²) or severe obesity (IMC=35-40 kg/m²) with co morbidities (sleep apnea syndrome or hypertension without treatment or steatosis hepatitis) candidates for a gastric bypass.
- Patient not receiving more than two treatments whose effect on the expression of enzymes and drug transporters is zero other than vitamins.
- Patient agreeing to participate at three studies of one day (12 hours) occurring at three different periods.
- Patients aged between 18 and 60 years old.
- Patient giving its well-informed and free consent.
- Patient without allergy to any of the drugs used for test.
- Patients living in France during the study and with French social security
Exclusion Criteria:
- Tabacco
- Contraception including estrogens compounds
- Medication other than vitamins.
- Allergy
Sites / Locations
- Unit of internal medicine A, Lariboisière Hospital
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
phenotypical approach
Arm Description
phenotypical approach
Outcomes
Primary Outcome Measures
Phenotypical markers of enzymes and transporter activity
plasmatic [Paraxanthine/caffeine] ratio (T4H) at 5-8 weeks following surgery. - plasmatic [Omeprazole/5-hydroxyomeprazole] ratio (T4H) at 5-8 weeks following surgery. - urinary Log (dextromethorphan/dextrorphan) (T0-T8h) at 5-8 weeks following surgery. - urinary Losartan/ E-3174 (T0-8h) at 5-8 weeks following surgery. - plasmatic AUC 0-inf midazolam at 5-8 weeks following surgery. - plasmatic AUC 0-inf digoxin at 5-8 weeks following surgery
Phenotypical markers of enzymes and transporter activity
plasmatic [Paraxanthine/caffeine] ratio (T4H) at 25-30 weeks following surgery. - plasmatic [Omeprazole/5-hydroxyomeprazole] ratio (T4H) at 25-30 weeks following surgery. - urinary Log (dextromethorphan/dextrorphan) (T0-T8h) at 25-30 weeks following surgery. - urinary Losartan/ E-3174 (T0-8h) at 25-30 weeks following surgery. - plasmatic AUC 0-inf midazolam at 25-30 weeks following surgery. - plasmatic AUC 0-inf digoxin at 25-30 weeks following surgery
Secondary Outcome Measures
Intestinal and hepatic expression and activity of the enzymes and transporter of interest and markers of inflammation
Intestinal and hepatic expression and activity of the enzymes and transporter of interest and markers of inflammation
Full Information
NCT ID
NCT01443039
First Posted
August 19, 2011
Last Updated
January 3, 2017
Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Ministry of Health, France
1. Study Identification
Unique Protocol Identification Number
NCT01443039
Brief Title
Phenotypical Approach of the Drug Metabolizing Hormones Activity Before and After Roux-en Y-Gastric Bypass
Acronym
SODA
Official Title
Phenotypical Approach of the Drug Metabolizing Hormones Activity (CYP1A2, CYP2D6, CYP2C9, CYP2C19, CYP3A4 and P-gp) Before and After Roux-en Y-Gastric Bypass. The SODA Protocol: Surgery for Obesity and Drug Availability
Study Type
Interventional
2. Study Status
Record Verification Date
December 2016
Overall Recruitment Status
Completed
Study Start Date
September 2011 (undefined)
Primary Completion Date
February 2014 (Actual)
Study Completion Date
February 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Ministry of Health, France
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The activity of drug-metabolizing enzymes and transporters evolutes after Roux-en-Y gastric Bypass.
Primary aim : To study the intra individual evolution of phenotypical markers of different drug metabolizing enzymes and one transporter (CYP1A2, CYP2D6, CYP2C9, CYP2C19, CYP3A4 and P-gp), using a cocktail phenotypic approach, after Roux-en-Y gastric Bypass.
Detailed Description
Principal Judgement criteria :
Phenotypical markers of enzymes and transporter activity before, at 5-8 weeks and 25-30 weeks following surgery.
Secondary judgement criteria :
Genetic polymorphisms known to affect expression and/or activity of enzymes and transporter.
Intestinal and hepatic expression and activity of the enzymes and transporter of interest.
Markers of inflammation Methodology, study design : open-labelled monocentric study.
Sample size : It will be a descriptive experimental study involving 12 subjects.
Study design : In centre 1: Inclusion at least 2 weeks prior to surgery (V0)
In centre 2: Three studies of 12 hours each will occur (in addition with the usual clinical and surgical follow up) at three times periods: in the 8 weeks period before surgery (V1), at 5-8 weeks after surgery (V2) and at 25-30 weeks after surgery (V3).
In centre 3: the patients will undergo gastric bypass surgery (corresponding to the usual clinical and surgical follow up) and samples of jejunum and liver will be obtain during the surgery (J0).
Centres 4 and 5 are involved in samples analysis.Hence, patients will attend 3 visits, in addition to the usual clinical and surgical follow-up.
Study duration: 26 months (with duration of inclusion of 18 months)
Duration for a patient: 38 weeks at maximum (8 months)
Investigating center and participating units: one center enrolling the patients and three centers involving in the others investigations.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
Keywords
drug metabolizing enzymes and drug transporter, Roux-en Y-Gastric Bypass, Obesity, Drug Availability, BMI over 35kg/m² and comorbidities or >40kg/m²
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
11 (Actual)
8. Arms, Groups, and Interventions
Arm Title
phenotypical approach
Arm Type
Experimental
Arm Description
phenotypical approach
Intervention Type
Drug
Intervention Name(s)
phenotypical approach
Intervention Description
each visit : CAFEINE : (solution orale) 2 ampoules de 2 ml = 100 mg de CAFEINE DEXTROMETHORPHANE : 15 ml de sirop contains 20 mg =>22,5 ml = 30mg Midazolam : (solution injectable, ampoule 1 ml = 1 mg) : deux ampoules = 2 mg Digoxine nativelle (solution injectable, ampoule de 0.5mg) : 1 ampoule per os = 0.5 mg Losartan 50 mg : 1cp de 50mg
Primary Outcome Measure Information:
Title
Phenotypical markers of enzymes and transporter activity
Description
plasmatic [Paraxanthine/caffeine] ratio (T4H) at 5-8 weeks following surgery. - plasmatic [Omeprazole/5-hydroxyomeprazole] ratio (T4H) at 5-8 weeks following surgery. - urinary Log (dextromethorphan/dextrorphan) (T0-T8h) at 5-8 weeks following surgery. - urinary Losartan/ E-3174 (T0-8h) at 5-8 weeks following surgery. - plasmatic AUC 0-inf midazolam at 5-8 weeks following surgery. - plasmatic AUC 0-inf digoxin at 5-8 weeks following surgery
Time Frame
at 5-8weeks
Title
Phenotypical markers of enzymes and transporter activity
Description
plasmatic [Paraxanthine/caffeine] ratio (T4H) at 25-30 weeks following surgery. - plasmatic [Omeprazole/5-hydroxyomeprazole] ratio (T4H) at 25-30 weeks following surgery. - urinary Log (dextromethorphan/dextrorphan) (T0-T8h) at 25-30 weeks following surgery. - urinary Losartan/ E-3174 (T0-8h) at 25-30 weeks following surgery. - plasmatic AUC 0-inf midazolam at 25-30 weeks following surgery. - plasmatic AUC 0-inf digoxin at 25-30 weeks following surgery
Time Frame
25-30 weeks
Secondary Outcome Measure Information:
Title
Intestinal and hepatic expression and activity of the enzymes and transporter of interest and markers of inflammation
Description
Intestinal and hepatic expression and activity of the enzymes and transporter of interest and markers of inflammation
Time Frame
before surgery
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients with morbid obesity (IMC > 40 kg/m²) or severe obesity (IMC=35-40 kg/m²) with co morbidities (sleep apnea syndrome or hypertension without treatment or steatosis hepatitis) candidates for a gastric bypass.
Patient not receiving more than two treatments whose effect on the expression of enzymes and drug transporters is zero other than vitamins.
Patient agreeing to participate at three studies of one day (12 hours) occurring at three different periods.
Patients aged between 18 and 60 years old.
Patient giving its well-informed and free consent.
Patient without allergy to any of the drugs used for test.
Patients living in France during the study and with French social security
Exclusion Criteria:
Tabacco
Contraception including estrogens compounds
Medication other than vitamins.
Allergy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Célia LLORET-LINARES, MD,
Organizational Affiliation
Assistance Publique - Hôpitaux de Paris
Official's Role
Principal Investigator
Facility Information:
Facility Name
Unit of internal medicine A, Lariboisière Hospital
City
Paris
ZIP/Postal Code
75010
Country
France
12. IPD Sharing Statement
Learn more about this trial
Phenotypical Approach of the Drug Metabolizing Hormones Activity Before and After Roux-en Y-Gastric Bypass
We'll reach out to this number within 24 hrs